<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342146</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci-004 CT</org_study_id>
    <nct_id>NCT01342146</nct_id>
  </id_info>
  <brief_title>Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children</brief_title>
  <acronym>PD</acronym>
  <official_title>Efficiency and Safety of Pegylated Somatropin(PEG-somatropin) in the Treatment of Children With Growth Hormone Deficiency: a Multicenter, Randomized, Open-label, Controlled Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the multicenter, randomized, open-label, controlled phase II study is to
      determine whether pegylated recombinant human growth hormone is effective in the treatment of
      children with growth hormone deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth velocity</measure>
    <time_frame>25 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>height standard deviation score for chronological age (Ht SDSCA)</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGFBP3</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">101</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated Somatropin</intervention_name>
    <description>0.1 mg/kg/wk once a week for 25 weeks</description>
    <other_name>PEG-rhGH,PEG-growth hormone,PEG-Somatropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated Somatropin</intervention_name>
    <description>0.2 mg/kg/wk once a week for 25 weeks</description>
    <other_name>PEG-rhGH,PEG-growth hormone,PEG-Somatropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jintropin AQ</intervention_name>
    <description>0.25 mg/kg/wk, once a day for 25 weeks</description>
    <other_name>Somatropin injectable solution,rhGH injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  have a height less than two standard deviations (SD) below the median height for
             individuals of the same age or height, a growth velocity (GV) ≤4 cm/yr, a GH peak
             concentration &lt;7 ng/ml in two different provocative tests, a bone age (BA; ≤9 years in
             girls and ≤10 years in boys) at least 2 years less than his/her chronological age
             (CA);

          -  be in preadolescence (Tanner stage 1) and have a CA &gt;3 years;

          -  have a height value recorded 3 months before the start of GH treatment to calculate
             pre-treatment GV;

          -  receive no prior GH treatment.

          -  sign informed consent

        Exclusion Criteria:

          -  patients with severe cardiopulmonary

          -  patients with hematological diseases

          -  a current or past history of malignant tumors

          -  immunodeficiency diseases

          -  mental diseases

          -  patients positive for hepatitis B e-antibody (HBeAb)

          -  hepatitis B surface antigen (HBsAg)

          -  hepatitis B e antigen (HBeAg)

          -  patients with other growth disorders, such as Turner syndrome

          -  constitutional delay of growth and puberty, and Laron syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoping Luo, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <link>
    <url>http://www.eje-online.org/content/177/2/195.full</url>
  </link>
  <results_reference>
    <citation>Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, Gong CX, Li Y, Du ML, Su Z, Du H, Yan C. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol. 2017 Aug;177(2):195-205. doi: 10.1530/EJE-16-0905. Epub 2017 May 31.</citation>
    <PMID>28566441</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <name_title>International Regulatory Affairs Department</name_title>
    <organization>GeneScience Pharmaceuticals Co., Ltd.</organization>
  </responsible_party>
  <keyword>pegylated Somatropin</keyword>
  <keyword>PEG-GH</keyword>
  <keyword>Growth hormone</keyword>
  <keyword>PEG-rhGH</keyword>
  <keyword>Growth hormone deficiency (GHD)</keyword>
  <keyword>Phase 2 study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

